WO2012009447A3 - THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF - Google Patents

THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF Download PDF

Info

Publication number
WO2012009447A3
WO2012009447A3 PCT/US2011/043873 US2011043873W WO2012009447A3 WO 2012009447 A3 WO2012009447 A3 WO 2012009447A3 US 2011043873 W US2011043873 W US 2011043873W WO 2012009447 A3 WO2012009447 A3 WO 2012009447A3
Authority
WO
WIPO (PCT)
Prior art keywords
hdac5
pka
camp
pathway
myopathies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/043873
Other languages
French (fr)
Other versions
WO2012009447A2 (en
Inventor
Zheng-Gen Jin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Priority to EP11807461.6A priority Critical patent/EP2593121A2/en
Priority to US13/809,789 priority patent/US20130156753A1/en
Publication of WO2012009447A2 publication Critical patent/WO2012009447A2/en
Publication of WO2012009447A3 publication Critical patent/WO2012009447A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11011—Protein-serine/threonine kinases (2.7.11) cAMP-dependent protein kinase (2.7.11.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

The present invention provides novel uses of the cAMP/PKA/HDAC5 pathway for the treatment and prevention of myopathies.
PCT/US2011/043873 2010-07-13 2011-07-13 THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF Ceased WO2012009447A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP11807461.6A EP2593121A2 (en) 2010-07-13 2011-07-13 THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
US13/809,789 US20130156753A1 (en) 2010-07-13 2011-07-31 THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36389510P 2010-07-13 2010-07-13
US61/363,895 2010-07-13

Publications (2)

Publication Number Publication Date
WO2012009447A2 WO2012009447A2 (en) 2012-01-19
WO2012009447A3 true WO2012009447A3 (en) 2012-07-19

Family

ID=45470058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/043873 Ceased WO2012009447A2 (en) 2010-07-13 2011-07-13 THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF

Country Status (3)

Country Link
US (1) US20130156753A1 (en)
EP (1) EP2593121A2 (en)
WO (1) WO2012009447A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
CA2927695C (en) * 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
CN106604747A (en) * 2014-08-26 2017-04-26 基础应用医学研究基金会 Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases
WO2016187507A1 (en) 2015-05-21 2016-11-24 The Chemours Company Fc, Llc HYDROFLUORINATION OF 1233xf TO 244bb BY SbF5
EP4354146B1 (en) 2015-10-19 2026-04-15 Takeda Pharmaceutical Company Limited Immunoassay for the detection of cleaved high molecular weight kininogen
CN114605497B (en) * 2021-02-10 2023-04-28 北京欣安诚科技有限公司 Artificial small interfering peptide of DAPK1 phosphorylated substrate and pharmaceutical application thereof
CN118217403B (en) * 2024-02-05 2025-04-18 中国人民解放军联勤保障部队第九〇四医院 Application of HDAC5 gene in regulating P-glycoprotein expression under hypoxia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632628B1 (en) * 1999-08-20 2003-10-14 Board Of Regents, The University Of Texas System Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632628B1 (en) * 1999-08-20 2003-10-14 Board Of Regents, The University Of Texas System Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARNEGIE, G.K. ET AL.: "AKAP-Lbc Mobilizes a Cardiac Hypertrophy Signaling Pathway.", MOLECULAR CELL., vol. 32, 2008, pages 169 - 179, XP055107924 *
MCKINSEY, T.A. ET AL.: "Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 97, no. 26, 2000, pages 14400 - 14405, XP055107923 *
ZHANG, C.L. ET AL.: "Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy.", CELL., vol. 110, 2002, pages 479 - 488, XP055107921 *

Also Published As

Publication number Publication date
US20130156753A1 (en) 2013-06-20
EP2593121A2 (en) 2013-05-22
WO2012009447A2 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
WO2012009447A3 (en) THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
WO2011072099A3 (en) Compositions and methods comprising protease variants
MY181898A (en) Heterocyclic compounds and uses thereof
WO2011140202A3 (en) Mif modulators
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2012055567A3 (en) Use of malononitrilamides in neuropathic pain
WO2012075286A9 (en) Intrapulmonary benzodiazepine for the treatment and prevention of seizures
WO2011130222A3 (en) Compositions and methods comprising variant proteases
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
EP4324527A3 (en) Formulations of enzalutamide
WO2012040499A3 (en) Metabolic inhibitors
WO2012064973A3 (en) Heterocyclic compounds and uses thereof
WO2012076293A9 (en) Formulations comprising polysiloxanes having nitrogen-containing groups
WO2012048176A3 (en) Attachment and retention formulations for biologically active organic compounds
IL224288A (en) Derivatives of substituted pyrazolamide, pharmaceutical compositions comprising the same and uses thereof
WO2010087947A3 (en) Transdermal delivery of diclofenac, carbamazepine and benzydamine
AP2013006984A0 (en) BicycloÄ3.2.1Üoctyl amide derivatives and uses of same
AP2011005637A0 (en) Carbazole compounds and therapeutic uses of the compounds.
WO2011006143A3 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria
WO2012173846A3 (en) Peptidomimetic macrocycles
HK1213471A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2011121576A3 (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
WO2012106427A3 (en) Methods for treating diabetic foot ulcers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11807461

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13809789

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011807461

Country of ref document: EP